Pharmaceuticals & Therapeutics

A landmark Medicare decision doubles payment for contrast-enhanced ultrasound, positioning the safer, cheaper alternative to challenge CT and MRI dominance.

Beyond M&A, ACROBiosystems' bioSeedin summit redefines growth, connecting global capital with biotech innovation in a new era of strategic partnerships.

Praxis and SEQSTER expand their alliance, leveraging a powerful data platform to speed up development of new treatments for epilepsy and other CNS disorders.

Serenity Mental Health Centers expands its ketamine therapy in Florida, offering rapid relief for depression but raising questions about cost and oversight.

Devonian appoints veteran CFO Dennis Turpin and corrects stock options, signaling a strategic shift as it aims to overcome financial hurdles and advance its pipeline.

A new collaboration adapts world-class cancer treatment standards for Vietnam, offering new hope for women battling breast and ovarian cancer.

vTv Therapeutics shores up its finances with a deal worth up to $135M, sharpening its focus on a breakthrough Type 1 diabetes drug, cadisegliatin.

A life-changing treatment for a rare kidney disease is now easily accessible in France, ending a long wait for patients and bolstering a French pharma firm.

A lawsuit seeks to block drastic cuts to Florida's ADAP program, which could strip thousands of life-saving HIV medication and insurance by March 1.

With an extra $3M, Aduro Clean Technologies advances its game-changing plant, turning investor confidence into a reality for recycling and energy.

NurExone appoints Eyal Gabbai, a healthcare and finance heavyweight, to its board, signaling a strategic pivot from R&D to market execution for its therapies.

Shane Kovacs's exit from Olema Oncology introduces leadership questions as the biotech firm nears a pivotal data readout for its lead breast cancer drug.

With its third Forbes nod, Jackson Healthcare's mix of strategic growth, tech, and culture reveals a model for navigating the healthcare crisis.

Promising Phase 2 data for a potential first-in-class neuropathic corneal pain therapy to be showcased, offering new hope for a debilitating condition.

After selling its proteomics arm to Illumina for $350M+, Standard BioTools is flush with cash but faces a pivotal moment to fix its core business.

ALX Oncology data shows CD47 levels predict response to evorpacept, offering new hope for heavily pretreated patients in a crowded therapeutic landscape.

Ruxolitinib cream's landmark approval in China marks a new era for vitiligo treatment, impacting patients, markets, and regulatory policy.

Facing a cash crunch after a major clinical trial setback, the cancer vaccine developer is exploring a sale or merger, putting its pipeline at risk.

After Amgen steps back, Kyowa Kirin takes full control of its promising atopic dermatitis drug, rocatinlimab, betting on its unique science.

Following the departure of its R&D head, Immunocore streamlines leadership, betting on internal experts to drive its next wave of innovative therapies.